Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes

被引：0

作者：

Pleyer, Lisa ^{[1
,2
]}

Burgstaller, Sonja ^{[3
]}

Stauder, Reinhard ^{[4
]}

Girschikofsky, Michael ^{[5
]}

Linkesch, Werner ^{[6
]}

Pfeilstoecker, Michael ^{[7
]}

Autzinger, Eva Maria ^{[8
]}

Tinchon, Christoph ^{[9
]}

Sliwa, Thamer ^{[7
]}

Lang, Alois ^{[10
]}

Sperr, Wolfgang R. ^{[11
]}

Geissler, Dietmar ^{[12
]}

Krippl, Peter ^{[13
]}

Voskova, Daniela ^{[14
]}

Rossmann, Dieter H. ^{[15
]}

Schlick, Konstantin ^{[16
]}

Thaler, Josef ^{[3
]}

Halter, Britta ^{[4
]}

Machherndl-Spandl, Sigrid ^{[5
]}

Theiler, Georg ^{[17
]}

Valent, Peter ^{[11
]}

Eckmuellner, Otto ^{[18
]}

Greil, Richard ^{[1
,19
]}

机构：

[1] Paracelsus Med Univ Salzburg, Salzburg, Austria

[2] Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Salzburg, Austria

[3] Klinikum Wels Grieskirchen, Wels, Austria

[4] Med Univ Innsbruck, A-6020 Innsbruck, Austria

[5] Elisabethinen Hosp, Linz, Austria

[6] Med Univ Graz, Graz, Austria

[7] Hanusch Hosp, Vienna, Austria

[8] Wilhelminenspital Stadt Wien, Vienna, Austria

[9] LKH Leoben, Leoben, Austria

[10] LKH Rankweil, Rankweil, Austria

[11] Med Univ Vienna, Vienna, Austria

[12] Klinikum Klagenfurt, Klagenfurt, Austria

[13] LKH Furstenfeld, Furstenfeld, Austria

[14] Gen Hosp Linz, Linz, Austria

[15] Hosp Steyr, Steyr, Austria

[16] PMU, Salzburg, Austria

[17] LKH Hartberg, Hartberg, Austria

[18] Forest Growth, Vienna, Austria

[19] Salzburg Canc Res Inst, Salzburg, Austria

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Prognostic implications of TdT expression in acute myeloid leukemia with an intermediate-risk karyotype
Masuho Saburi
Masao Ogata
Takako Satou
Yasuhiro Soga
Kazuhito Itani
Kazuhiro Kohno
Yoshiyuki Kondo
Toshiyuki Nakayama
International Journal of Hematology, 2020, 112 : 17 - 23
[32] Prognostic implications of TdT expression in acute myeloid leukemia with an intermediate-risk karyotype
Saburi, Masuho
Ogata, Masao
Satou, Takako
Soga, Yasuhiro
Itani, Kazuhito
Kohno, Kazuhiro
Kondo, Yoshiyuki
Nakayama, Toshiyuki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 112 (01) : 17 - 23
[33] Improved Outcome of Patients With Low- and Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML) in First Relapse With Gemtuzumab and Cytarabine Versus Cytarabine
Prebet, Thomas
Etienne, Anne
Devillier, Raynier
Romeo, Emilie
Charbonnier, Aude
D'incan, Evelyne
Esterni, Benjamin
Arnoulet, Christine
Blaise, Didier
Vey, Norbert
CANCER, 2011, 117 (05) : 974 - 981
[34] Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics
Fukuno, Kenji
Hara, Takeshi
Tsurumi, Hisashi
Shibata, Yuhei
Mabuchi, Ryoko
Nakamura, Nobuhiko
Kitagawa, Junichi
Shimizu, Masahito
Ito, Hiroyasu
Saito, Kuniaki
Moriwaki, Hisataka
LEUKEMIA & LYMPHOMA, 2015, 56 (05) : 1398 - 1405
[35] Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing
Wang, Bianhong
Liu, Yangyang
Hou, Guangyuan
Wang, Lili
Lv, Na
Xu, Yuanyuan
Xu, Yihan
Wang, Xiuli
Xuan, Zhaoling
Jing, Yu
Li, Honghua
Jin, Xiangshu
Deng, Ailing
Wang, Li
Gao, Xiaoning
Dou, Liping
Liang, Junbin
Chen, Chongjian
Li, Yonghui
Yu, Li
ONCOTARGET, 2016, 7 (22) : 32065 - 32078
[36] Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study
Merkel, Drorit
Filanovsky, Kalman
Gafter-Gvili, Anat
Vidal, Liat
Aviv, Ariel
Gatt, Moshe E.
Silbershatz, Itay
Herishanu, Yair
Arad, Ariela
Tadmor, Tamar
Dally, Najib
Nemets, Anatoly
Rouvio, Ory
Ronson, Aharon
Herzog-Tzarfati, Katrin
Akria, Luiza
Braester, Andrei
Hellmann, Ilana
Yeganeh, Shay
Nagler, Arnon
Leiba, Ronit
Mittelman, Moshe
Ofran, Yishai
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (02) : 130 - 134
[37] Evolving treatment strategies in patients with high-risk acute myeloid leukemia
Schiller, Gary J.
LEUKEMIA & LYMPHOMA, 2014, 55 (11) : 2438 - 2448
[38] Code status transitions in patients with high-risk acute myeloid leukemia
Abrams, Hannah R.
Nipp, Ryan D.
Traeger, Lara
Lavoie, Mitchell W.
Reynolds, Matthew J.
Ufere, Nneka N.
Wang, Annie C.
Boateng, Kofi
LeBlanc, Thomas W.
El-Jawahri, Areej
BLOOD ADVANCES, 2022, 6 (14) : 4208 - 4215
[39] Distress and Perceived Impact on Well-Being for Low- or Intermediate-Risk and High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)
Buzaglo, Joanne S.
Miller, Melissa F.
Karten, Clare
Weiss, Elisa S.
Tomlinson, Brian
Andersen, Barbara L.
Matasar, Matthew J.
Byrd, John C.
Flowers, Christopher
BLOOD, 2016, 128 (22)
[40] A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia
Cahill, Kirk E.
Karimi, Yasmin H.
Karrison, Theodore G.
Jain, Nitin
Green, Margaret
Weiner, Howard
Fulton, Noreen
Kadri, Sabah
Godley, Lucy A.
Artz, Andrew S.
Liu, Hongtao
Thirman, Michael J.
Le Beau, Michelle M.
McNerney, Megan E.
Segal, Jeremy
Larson, Richard A.
Stock, Wendy
Odenike, Olatoyosi
BLOOD ADVANCES, 2020, 4 (04) : 599 - 606

← 1 2 3 4 5 →